Role of 6‐phosphogluconate dehydrogenase enzyme 1 in growth and virulence of Toxoplasma gondii and development of attenuated live vaccine
Microbial Biotechnology · 2023
DOI: 10.1111/1751-7915.14324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, 2023. Verfasst von Qinghong Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China. Hauptthemen laut MEDLINE: Toxoplasma, Phosphogluconate Dehydrogenase, Protozoan Vaccines, Toxoplasmosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Major Project of Basic and Applied Basic Research, Laboratory for Lingnan Modern Agriculture Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Toxoplasma gondii is a ubiquitous pathogen that infects all warm‐blooded animals, including humans, causing substantial socioeconomic and healthcare burdens. However, there is no ideal vaccine for toxoplasmosis. As metabolism is important in the growth and virulence of Toxoplasma , some key pathways are promising antiparasitic targets. Here, we identified 6‐phosphogluconate dehydrogenase 1 ( Tg 6PGDH1) in the oxidative pentose phosphate pathway as a cytoplasmic protein that is dispensable for tachyzoite growth of T. gondii in vitro but critical for virulence and cyst formation in vivo. The depletion of Tg 6PGDH1 causes decreased gene transcription involved in signal transduction, transcriptional regulation and virulence. Furthermore, we analysed the protective effect of the ME49 Δ6pgdh1 mutant as an attenuated vaccine and found that ME49 Δ6pgdh1 immunization stimulated strong protective immunity against lethal challenges and blocked cyst formation caused by reinfection. Furthermore, we showed that ME49 Δ6pgdh1 immunization stimulated increased levels of interferon‐gamma, tumour necrosis factor‐alpha and Toxoplasma‐ specific IgG antibodies. These data highlight the role of Tg 6PGDH1 in the growth and virulence of T. gondii and its potential as a target for the development of a live‐attenuated vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
- State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
ORCID-Profile: Ningbo Xia
Förderung
- Guangdong Major Project of Basic and Applied Basic Research
- Laboratory for Lingnan Modern Agriculture Project
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Science and Technology Program of Guangzhou, China
Zitieren
APA
Guo, Q., Guo, X., Ji, N., Shen, B., Zhong, X., Xiao, L., Feng, Y., & Xia, N. (2023). Role of 6‐phosphogluconate dehydrogenase enzyme 1 in growth and virulence of Toxoplasma gondii and development of attenuated live vaccine. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.14324
Vancouver
Guo Q, Guo X, Ji N, Shen B, Zhong X, Xiao L, et al. Role of 6‐phosphogluconate dehydrogenase enzyme 1 in growth and virulence of Toxoplasma gondii and development of attenuated live vaccine. Microbial Biotechnology. 2023. doi:10.1111/1751-7915.14324
BibTeX
@article{Guo2023,
author = {Guo, Qinghong and Guo, Xuefang and Ji, Nuo and Shen, Bang and Zhong, Xinhua and Xiao, Lihua and Feng, Yaoyu and Xia, Ningbo},
title = {Role of 6‐phosphogluconate dehydrogenase enzyme 1 in growth and virulence of Toxoplasma gondii and development of attenuated live vaccine},
journal = {Microbial Biotechnology},
year = {2023},
doi = {10.1111/1751-7915.14324}
}
EUVIMED